ArticleUrolithiasis2025
Antiurolithic activity of vanillin in ethylene glycol-induced hyperoxaluric rat model.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protective effects of Rhus coriaria L. fruit extract against experimental calcium oxalate nephrolithiasis via modulation of oxidative stress and renal injury.Urolithiasis · 2026Article
- Oxidative stress, inflammation and kidney stones.Urolithiasis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Vanillin, a natural compound derived from vanilla beans, exhibits antioxidant and anti-inflammatory properties, which may contribute to the prevention and treatment of renal stones. Therefore, this study is aimed to investigate the potential antiurolithic effect of vanillin in male hyperoxaluric Wistar rats. Computational molecular docking studies were used to investigate the interaction process and verify vanillin's role in the prevention of kidney stones containing calcium oxalate. Software tools were utilized to analyze the drug ligands' additional molecular characteristics, absorption, distribution, metabolism, and excretion (ADME), and toxicity. Urinary crystals were induced in rats by adding 0.75% ethylene glycol (EG) in drinking water for 3 weeks, along with 1% ammonium chloride (AC) during the initial three days. Molecular docking analysis revealed strong binding interactions of vanillin with Human CTP: Phosphoethanolamine Cytidylyltransferase (PDB ID: 3ELB) at the C5P binding site, with a binding affinity of -7.6 kcal/mol, suggesting a potential molecular basis for its antiurolithic activity. In vivo study showed that vanillin treatment dose dependently (30, 100 and 300 mg/kg body weight) reduced hyperoxaluria, hypercalciuria and crystal counts in kidneys of hyperoxaluric rats. The current results of our study suggest that vanillin possesses potential antiurolithic activity, showing enhanced therapeutic effects in urolithiasis, which could be a safe, effective and non-invasive option in modern medicine for the management of urinary stones.
Indexed as
Identifiers
40116953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.